



Gene Expression Profiling for Breast Cancer — MammaPrint®

Last Review Date: June 18, 2014

Number: MG.MM.LA.12c

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

MammaPrint® is a qualitative in vitro diagnostic test service, performed in a central laboratory, using the gene expression profile of fresh breast cancer tissue samples to assess a patients' risk for distant metastasis (up to 10 years for patients less than 61 years old, up to 5 years for patients ≥ 61 years).

Guideline

Members with Stage 1 or Stage 2 invasive breast cancer breast cancer are eligible for MammaPrint coverage for recurrence risk prediction when the following criteria are met:

1. Tumor size < 5.0 cm
2. ER+ or ER-
3. 0–3 local lymph nodes involved with nodal micrometastases (< 2.0 mm [Stage pN1])

Limitations/Exclusions

1. MammaPrint is not considered medically necessary adjuvant therapy treatment planning.
2. Repeat testing and indications other than those listed above are not considered medically necessary.
3. Tests for genetic expression profiling *other* than the MammaPrint or Oncotype® DX Breast Cancer Assay (see EmblemHealth's [Oncotype guideline](#)) are not considered medically necessary (i.e., BluePrint™, HerMark® [covered for Medicare members only], H:I ratio, Rotterdam/Veridex 76-gene prognostic signature, HOX13:IL17BR [two-gene signature]).

4. The MammaPrint test is not considered reasonable and necessary \geq 6 months post diagnosis, or if chemotherapy has been initiated, as clinical utility has not been established when chemotherapy is delayed.

Applicable Procedure Codes

81519	Use for Medicare
	Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score (New code effective 01/01/2015)
S3854	Use for Commercial
	Gene expression profiling panel for use in the management of breast cancer treatment

References

FDA. 510(k) Substantial Equivalence Determination Decision Summary. 2007.

http://www.accessdata.fda.gov/cdrh_docs/reviews/k101454.pdf. Accessed July 11, 2013.

National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology™. Breast cancer. Version.2.2015. Available at:

http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed June 2, 2015.

Palmetto GBA. MammaPrint Billing and Coding Guidelines Update. September 2014.

http://www.palmettogba.com/palmetto/MolDX.nsf/DocsCat/MolDX%20Website~MolDx~Browse%20By%20Topic~Covered%20Tests~8SBH3U4732?open&navmenu=Browse^By^Topic|_|_|http://www.palmettogba.com/palmetto/providers.nsf/DocsCat/Providers~Jurisdiction%2011%20Part%20B~Browse%20by%20Topic~Lab~8SBH5V8350?open&navmenu=%7C%7C. Accessed June 16, 2015

Specialty-matched clinical peer review.